PRME Prime Medicine, Inc.
8-K Current Report
Filed: March 3, 2026
Health Care
Biological Products, (No Diagnostic Substances)Prime Medicine, Inc. (PRME) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Full-year 2025 financial results released March 3, 2026 — details in Exhibit 99.1 press release
- • PRME is a clinical-stage gene editing company; earnings releases signal cash runway and pipeline progress, key investor metrics
Item 7.01 · Regulation FD Disclosure
- • Corporate presentation updated March 3, 2026, posted to investor relations website
- • Full presentation available as Exhibit 99.2 in this 8-K filing for detailed strategic/pipeline updates
Get deeper insights on Prime Medicine, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.